MiR-3121-3p Promotes Tumor Invasion and Metastasis by Suppressing Rap1GAP in Papillary Thyroid Cancer

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Nov 12

PMID 33178761

Citations 7

Authors

Ming Xu

Jun Zhou

Qiulei Zhang

Kehao Le

Zihan Xi

Pengfei Yi

Xiangwang Zhao

Jie Tan

Tao Huang

Affiliations

Soon will be listed here.

Abstract

Background: Rap1GAP is a tumor suppressor and is downregulated in human malignancies including papillary thyroid cancer (PTC). The mechanism of its suppression in PTC remains unclear.

Methods: Bioinformatic analyses were carried out to evaluate clinical significance and to predict upstream miRNA bindings of Rap1GAP. Three PTC cell lines, TPC-1, B-CPAP, and K1, were employed for functional verification and further experiments. We used dual-luciferase reporter gene assay to confirm the miRNA binding prediction, Western blotting and quantitative polymerase chain reaction (qPCR) to explore miRNA and Rap1GAP regulation, Transwell and wound healing assays to compare cell migration and invasion after protein knockout or overexpression, and Cell Counting Kit-8 (CCK-8) assay to evaluate cell proliferation.

Results: Rap1GAP expression was suppressed in thyroid cancer compared to adjacent normal tissues and was a potential diagnostic marker of PTC. Rap1GAP suppression was correlated to younger age, advanced T stage, N stage, extrathyroidal extension, BRAF-like tumors, and higher risk of recurrence. Combined analysis of bioinformatic prediction and dual-luciferase assay revealed binding between miR-3121-3p with 3'UTR of Rap1GAP promoter. MiR-3121-3p promoted cell migration, invasion, and proliferation via inhibiting Rap1GAP and thus upregulating MAPK pathway. Overexpression and knockdown of Rap1GAP could counteract the influence on cell migration and invasion carried out by miR-3121-3p mimic and inhibitor, respectively. Rap1GAP partially impaired the effect of miR-3121-3p in cell growth in the CCK-8 assay.

Conclusions: Rap1GAP expression is suppressed in PTC and is a potential diagnostic marker. Its upstream regulator, miR-3121-3p, affects tumor metastasis and proliferation via regulating Rap1GAP expression. MAPK signaling pathway may be involved in this effect.

Citing Articles

The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

Zhang T, Yuan B, Yu S Int J Gen Med. 2024; 17:4681-4699.

PMID: 39429957 PMC: 11490214. DOI: 10.2147/IJGM.S487239.

Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.

Zhang L, Li Z, Zhang M, Zou H, Bai Y, Liu Y Med Oncol. 2023; 40(9):258.

PMID: 37524925 DOI: 10.1007/s12032-023-02098-3.

Evaluation of and Gene Expression in Endometriosis Disease.

Dehghanian M, Yarahmadi G, Sandoghsaz R, Khodadadian A, Shamsi F, Vahidi Mehrjardi M Adv Biomed Res. 2023; 12:101.

PMID: 37288024 PMC: 10241619. DOI: 10.4103/abr.abr_86_22.

Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.

Ghanbarzehi A, Sepehrinezhad A, Hashemi N, Karimi M, Shahbazi A BMC Psychiatry. 2023; 23(1):40.

PMID: 36641432 PMC: 9840830. DOI: 10.1186/s12888-023-04543-z.

Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.

Yi Q, Peng J, Xu Z, Liang Q, Cai Y, Peng B Front Bioeng Biotechnol. 2022; 10:806851.

PMID: 35910024 PMC: 9329936. DOI: 10.3389/fbioe.2022.806851.

References

Yasui T, Yanagida T, Ito S, Konakade Y, Takeshita D, Naganawa T . Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires. Sci Adv. 2018; 3(12):e1701133. PMC: 5744465. DOI: 10.1126/sciadv.1701133. View

Tsygankova O, Feshchenko E, Klein P, Meinkoth J . Thyroid-stimulating hormone/cAMP and glycogen synthase kinase 3beta elicit opposing effects on Rap1GAP stability. J Biol Chem. 2003; 279(7):5501-7. DOI: 10.1074/jbc.M305824200. View

Sukegawa M, Wang X, Nishioka C, Pan B, Xu K, Ohkawara H . The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. Leuk Res. 2017; 58:83-90. DOI: 10.1016/j.leukres.2017.05.005. View

Lee J, Gundara J, Glover A, Serpell J, Sidhu S . MicroRNA expression profiles in the management of papillary thyroid cancer. Oncologist. 2014; 19(11):1141-7. PMC: 4221366. DOI: 10.1634/theoncologist.2014-0135. View

Liu R, Xing M . TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23(3):R143-55. PMC: 4750651. DOI: 10.1530/ERC-15-0533. View

Maimaiti Y, Jie T, Jing Z, Changwen W, Pan Y, Chen C . Aurora kinase A induces papillary thyroid cancer lymph node metastasis by promoting cofilin-1 activity. Biochem Biophys Res Commun. 2016; 473(1):212-218. DOI: 10.1016/j.bbrc.2016.03.081. View

Tokar T, Pastrello C, Rossos A, Abovsky M, Hauschild A, Tsay M . mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2017; 46(D1):D360-D370. PMC: 5753284. DOI: 10.1093/nar/gkx1144. View

Cilek E, Ozturk H, Gur Dedeoglu B . Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines. PLoS One. 2017; 12(10):e0185558. PMC: 5628841. DOI: 10.1371/journal.pone.0185558. View

Nellore A, Paziana K, Ma C, Tsygankova O, Wang Y, Puttaswamy K . Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab. 2008; 94(3):1026-32. PMC: 2681278. DOI: 10.1210/jc.2008-1042. View

10.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

11.

Tuttle R, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M . Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid.... Thyroid. 2010; 20(12):1341-9. PMC: 4845674. DOI: 10.1089/thy.2010.0178. View

12.

Dorard C, Cseh B, Ehrenreiter K, Wimmer R, Varga A, Hirschmugl T . RAF dimers control vascular permeability and cytoskeletal rearrangements at endothelial cell-cell junctions. FEBS J. 2019; 286(12):2277-2294. PMC: 6617973. DOI: 10.1111/febs.14802. View

13.

Daumke O, Weyand M, Chakrabarti P, Vetter I, Wittinghofer A . The GTPase-activating protein Rap1GAP uses a catalytic asparagine. Nature. 2004; 429(6988):197-201. DOI: 10.1038/nature02505. View

14.

Xing M . BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-62. DOI: 10.1210/er.2007-0007. View

15.

Wojcicka A, Kolanowska M, Jazdzewski K . MECHANISMS IN ENDOCRINOLOGY: MicroRNA in diagnostics and therapy of thyroid cancer. Eur J Endocrinol. 2015; 174(3):R89-98. DOI: 10.1530/EJE-15-0647. View

16.

Dong X, Tang W, Stopenski S, Brose M, Korch C, Meinkoth J . RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer. 2012; 19(4):575-88. PMC: 3531979. DOI: 10.1530/ERC-12-0086. View

17.

Gao W, Ye G, Liu L, Wei L . The downregulation of Rap1 GTPase-activating protein is associated with a poor prognosis in colorectal cancer and may impact on tumor progression. Oncol Lett. 2018; 15(5):7661-7668. PMC: 5920375. DOI: 10.3892/ol.2018.8305. View

18.

Xing M . Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13(3):184-99. PMC: 3791171. DOI: 10.1038/nrc3431. View

19.

Rubinfeld B, Crosier W, Albert I, Conroy L, Clark R, McCormick F . Localization of the rap1GAP catalytic domain and sites of phosphorylation by mutational analysis. Mol Cell Biol. 1992; 12(10):4634-42. PMC: 360390. DOI: 10.1128/mcb.12.10.4634-4642.1992. View

20.

de Koster E, de Geus-Oei L, Dekkers O, van Engen-van Grunsven I, Hamming J, Corssmit E . Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev. 2018; 39(2):154-191. DOI: 10.1210/er.2017-00133. View